Tracer library / [68Ga]Ga-DOTATATE
[68Ga]Ga-DOTATATE
Also written as [68Ga]DOTATATE; [68Ga]Ga-DOTA-TATE; [68Ga]Ga-DOTATATE; [Ga-68]DOTATATE; [Ga-68]Ga-DOTA-TATE; [Ga-68]Ga-DOTATATE; DOTA-(Tyr3)-octreotate
- Radionuclide
- Ga-68 t½ 67.7 min
- Modality
- PET
- Production route
- Generator / Cyclotron solid target
- Stage
- Approved
- Syntheses indexed
- 26
What it is
- Compound class
- Peptide (somatostatin analogue)
- Target / mechanism
- Somatostatin receptor subtype 2 (SSTR2) PMID 28547177 / DOI 10.1007/s00259-017-3728-y
- Clinical application
- Neuroendocrine neoplasms (diagnosis, staging, selection for PRRT); also SSTR-expressing meningioma PMID 28547177 / DOI 10.1007/s00259-017-3728-y; PMC11445317 (EANM/EANO/RANO/SNMMI meningioma SSTR-ligand guideline v1.0)
- Theranostic pair
- [177Lu]Lu-DOTATATE
Regulatory status
- FDA
- Yes — 2016; NETSPOT (kit for gallium Ga 68 dotatate); Advanced Accelerator Applications USA (Novartis); NDA 208547 Drugs@FDA, NDA 208547, approved 2016-06-01 — https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process&searchTerm=dotatate
- EMA (centralised)
- No EMA medicines register — no centrally authorised gallium (68Ga) dotatate / oxodotreotide; search: https://www.ema.europa.eu/en/medicines?search_api_fulltext=gallium+dotatate
- Other approvals
- —
- Brand names
- NETSPOT (US, FDA)
Clinical use
- Typical injected activity
- 100-200 MBq (~2 MBq/kg; EANM guideline) PMID 28547177 / DOI 10.1007/s00259-017-3728-y
- Uptake time
- 45-90 min post-injection (typically 60 min) PMID 28547177 / DOI 10.1007/s00259-017-3728-y; PMID 31343614 / DOI 10.1097/MNM.0000000000001048
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| EasyOne Trasis | vendor cassette | SPE | 91 ± 5% decay-corrected | >99.3% | DOTATATE ABX | 41701433 2026 EJNMMI Radiopharm Chem [68Ga]Ga-DOTATATE was synthesized using Trasis EasyOne synthesizer as follows - The corrected yield of the labelled products was 91 ± 5% (72 ± 5% non-decay corrected). |
| Modular-Lab Standard Eckert & Ziegler | fixed tubing | SPE | 84.4±1.2% not corrected | 99.1±0.3% | DOTA-TATE piCHEM, Raaba-Grambach, Austria | 39050235 2024 Asia Ocean J Nucl Med Biol Automated radiosynthesis module (Modular-Lab Standard) was from Eckert & Ziegler, Germany. - [68Ga]Ga-DOTATATE were found to be...(84.4±1.2)% (n=504) |
| — | — | none | 99%±1% | >98% | DOTATATE Bachem, Bubendorf, Switzerland | 26702783 2016 Nucl Med Biol |
| Modular-Lab PharmTracer Eckert & Ziegler | vendor cassette | SPE | 87.9±0.4% | >99.5% | DOTATATE (DOTA-(Tyr3)-octreotate) AUSPEP | 27408863 2014 Asia Ocean J Nucl Med Biol Eckert & Ziegler Eurotope's Modular-Lab Pharm Tracer® automated synthesis system - Ga-68 DOTATATE yields for 2011, 2012, and 2013 were 81.8±0.4%, 82.2±0.4% and 87.9±0.4%, respectively. |
| FASTlab GE HealthCare | — | SPE | 67.81±3.12 decay-corrected | 99.68±0.13 | DOTATATE ABX | 25369268 2014 PLoS One Most of the synthesis was performed using an automated process programmed in a FastLab module (General Electric Healthcare). - the decay-corrected radiochemical yield (%) was 54.03±2.45, 66.13±3.35 and 67.81±3.12 |
| Scintomics GRP / GRP-3V Scintomics | vendor cassette | SPE | 63.66% (mean); 63.34%, 63.71%, 64.01% | 99.45% 99.78%, 99.75% | DOTATATE ABX | 33642752 2020 Indian J Nucl Med fully automated module (Scintomics GRP®, Fürstenfeldbruck, Germany) specifically designed for the synthesis of radiopharmaceuticals - Our validation runs of Ga-68-DOTATATE have demonstrated highly reproducible synthesis yields (mean value 63.66%). |
| AllinOne (AiO) Trasis | vendor cassette | SPE | 66% ± 5% decay-corrected | 98.4% ± 0.9% | DOTATATE AUSPEP | 35906092 2023 J Nucl Med performed on an AllInOne automated module (TRASIS), as shown in Figure 2 - for a global decay-corrected yield of 66% ± 5% (n = 14) |
| Modular-Lab (model not stated) Eckert & Ziegler | — | — | — | — | DOTATATE AUSPEP | 35906092 2023 J Nucl Med fractionized with the Eckert and Ziegler module in the clean room |
| Manual synthesis | — | SPE | 81 ± 3% decay-corrected | 99.8 ± 0.2% | DOTA-TATE Nanchang Tanzhen Biological Technology Co., Ltd., China | 41764676 2026 EJNMMI Radiopharm Chem Radiolabeling of 68Ga with DOTA-TATE, Pentixafor and FAP-2286 was performed manually using a similar operating procedure - 81 ± 3% |
| EasyOne Trasis | vendor cassette | SPE | 90.95 decay-corrected | >99.7% | DOTATATE-peptide ABX | 41701433 2026 EJNMMI Radiopharm Chem [68Ga]Ga-DOTATATE was synthesized using Trasis EasyOne synthesizer - Yield %N/A90.95%90,32%91,06% |
| Modular-Lab Standard Eckert & Ziegler | vendor cassette | SPE | 89.03±3.78 | 98.69±1.24 | DOTATATE acetate ABX | 41370506 2025 Einstein (Sao Paulo) A Modular-Lab Standard synthesis module (Eckert & Ziegler, Berlin, Germany) was successfully installed and implemented in November 2013 - Labeling Yield (%)89.03±3.78 |
| Manual synthesis | — | SPE | — | >99% | DOTA-TATE | 39770488 2024 Pharmaceuticals (Basel) During the labeling process, the generator was rinsed with 2 mL of 0.05 M HCl, and the waste solution was discarded. |
| Manual synthesis | — | HPLC | — | >96 % | DOTA-TATE Bachem, Bubendorf, Switzerland | 39310112 2024 Theranostics Radiolabeling of SSTR2 ligands with gallium‑68 and copper‑64 was performed in ammonium acetate buffer (2.0 mol/L, pH 4.5 and pH 5.3, respectively) at 80 °C for 20 min. |
| Modular-Lab Standard Eckert & Ziegler | fixed tubing | SPE | 84.4±1.2% not corrected | 99.1±0.3% | DOTA-TATE piCHEM, Raaba-Grambach, Austria | 39050235 2024 Asia Ocean J Nucl Med Biol Automated radiosynthesis module (Modular-Lab Standard) was from Eckert & Ziegler, Germany. - [68Ga]Ga-DOTATATE were found to be ... (84.4±1.2)% (n=504) |
| Scintomics GRP / GRP-3V Scintomics | vendor cassette | SPE | — | — | DOTATATE ABX | 35889351 2022 Molecules the automated synthesis module Scintomics GRPTM (Scintomics GmbH, Fürstenfeldbruck, Germany) |
| Manual synthesis | — | HPLC+SPE | 62% decay-corrected | >98% | DOTATATE In-house / non-commercial (various) | 29503845 2017 EJNMMI Radiopharm Chem heated in a microwave oven (catalog number: DMW7700WDB, Danby Appliance, Findlay, Ohio) - 61 ± 5, 62 ± 8 and 68 ± 13% respectively, n = 3 |
| FASTlab GE HealthCare | — | SPE | 67.81 decay-corrected | 99.68 | DOTATATE ABX | 25369268 2014 PLoS One Most of the synthesis was performed using an automated process programmed in a FastLab module (General Electric Healthcare). - 67.8% for 68Ga-DOTATATE |
| Kit-based preparation n/a (commercial cold kit, various vendors) | — | — | 1.35 GBq | — | [68Ga]GaCl3 | 38447298 2024 Nucl Med Biol compatibility of the [68Ga]GaCl3 with NetSpot and Illuccix kits was investigated - 0.55 mL of buffer was added to 4.2 mL of [68Ga]GaCl3 which gave 1.35 GBq of formulated product |
| — | — | HPLC | — | — | DOTA-TATE | 37218205 2023 Curr Radiopharm |
| — | — | HPLC | 63.68 | 98 ± 0.22% | DOTATATE | 35190517 2022 Nucl Med Commun |
| AllinOne (AiO) Trasis | — | — | 71 ± 5.8 % | >97 % | — | 40349649 2025 Appl Radiat Isot using the AllinOne 36-valve synthesis module - For [68Ga]Ga-DOTA-TATE, the yield was 71 ± 5.8 % with synthesis times about 18 min (n = 3) |
| Scintomics GRP / GRP-3V Scintomics | — | — | — | — | — | 24120219 2014 Nucl Med Biol using a SCINTOMICS GRP module and an iThemba Labs generator |
| — | — | none | >80% | — | DOTATATE | 22755505 2012 Bioconjug Chem The NaCl method was further evaluated using an automated fluid handling system - radiochemical yields greater than 80% |
| — | — | — | >70% | — | DOTA-TATE | 31421441 2019 Nucl Med Biol [68Ga]Ga-DOTA-TATE labelling was incorporated to give 1.56 GBq at EOS of the labelled peptide - RCY of >70% |
| Synthera IBA | — | — | >99% | >99% | — | 22149590 2012 Cancer Biother Radiopharm reprogramming and adaptation of a commercially available synthetic module (IBA molecular; Synthera®) allowed high yield, fully automated, in-house radiolabeling - (68)Ga-octreotate and (177)Lu-octreotate were synthesized, resulting in both radiochemical yield and radiochemical purity greater than 99%. |
| Manual synthesis n/a | — | — | 75.9 ± 1.8% | — | DOTA-TATE | 42229087 2026 Nucl Med Biol Manual [68Ga]Ga-DOTA-TATE labeling - Manual [68Ga]Ga-DOTA-TATE labeling yield increased from 58.9 ± 6% to 75.9 ± 1.8% (n = 10). |
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- Lanreotide versus placebo for tumour reduction in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): a randomised, multicentre, phase 3 trial with blinded outcome assessment.2024 · Lancet Reg Health Eur · Multicentre · Phase III
- Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience - do we need [18F]FDG PET/CT for qualification to PRRT?2020 · Endokrynol Pol · Multicentre
- 18F-FDOPA PET/CT for neuroendocrine tumors in multiple endocrine neoplasia type 1.2026 · Front Endocrinol (Lausanne) · Prospective
- Preliminary Evaluation of 225 Ac/ 177 Lu-DOTATATE PRRT in Progressive Meningiomas : Efficacy, Dosimetry, and Imaging Insights.2026 · Clin Nucl Med · Prospective
- Somatostatin Receptor Expression on [68Ga]Ga-DOTATATE PET Among Patients with Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas: A Prospective Study.2026 · J Nucl Med · Prospective
- Head-to-Head Comparison of [ 18 F]MFBG and [ 68 Ga]Ga-DOTA-TATE PET/CT in Suspected Recurrent/Refractory Neuroblastoma: Prospective Single-center Analysis.2026 · Clin Nucl Med · Prospective
- Head-to-Head comparison of [18F]AlF-NOTA-TATE and [68Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors: a prospective study.2026 · Eur J Nucl Med Mol Imaging · Prospective
- The SCARLET trial: a prospective phase II study of somatostatin receptor imaging for potential radiotheranostic application in patients with relapsing and refractory multiple myeloma.2026 · Eur J Nucl Med Mol Imaging · Prospective · Phase II
- Assessment of the diagnostic efficacy and clinical significance of [18F]AlF-NOTA-LM3 PET/CT in patients with well-differentiated neuroendocrine tumors.2026 · Eur J Nucl Med Mol Imaging · Prospective
- [18F]MFBG PET/CT is an effective and preferable imaging modality for neuroblastoma in a prospective comparison with SSTR PET.2026 · Eur J Nucl Med Mol Imaging · Prospective
Show all 155 clinical studies
- Comparison of PET/CT using 68Ga-NOTA-Exendin-4 with 68Ga-DOTATATE, 18F-FDG, and conventional imaging in the localization of insulinomas.2025 · Eur J Nucl Med Mol Imaging · Prospective
- Gallium-68-DOTATATE PET/CT for phosphaturic mesenchymal tumor localization in suspected tumor-induced osteomalacia.2025 · JBMR Plus · Prospective, retrospective
- Somatostatin receptor-targeted theranostics in patients with estrogen receptor-positive metastatic breast cancer-a prospective exploratory study.2025 · Breast Cancer Res Treat · Prospective
- Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.2024 · J Nucl Med · Prospective
- Dual Somatostatin Receptor/18F-FDG PET/CT Imaging in Patients with Well-Differentiated, Grade 2 and 3 Gastroenteropancreatic Neuroendocrine Tumors.2024 · J Nucl Med · Prospective
- 68 Ga-DOTATATE PET/CT Versus 18 F-FDG PET/CT in TENIS Syndrome: A Head-to-Head Comparison With Elevated and Suppressed TSH Levels in Papillary Thyroid Carcinoma-A Pilot Study.2024 · Clin Nucl Med · Prospective
- Quantitative Assessments of Tumor Activity in a General Oncologic PET/CT Population: Which Metric Minimizes Tracer Uptake Time Dependence?2024 · J Nucl Med · Prospective
- Evaluation of the safety, biodistribution, dosimetry of [18F]AlF-NOTA-LM3 and head-to-head comparison with [68Ga]Ga-DOTATATE in patients with well-differentiated neuroendocrine tumors: an interim analysis of a prospective trial.2024 · Eur J Nucl Med Mol Imaging · Prospective
- A head-to-head comparison of [68Ga]Ga-DOTATATE and [68Ga]Ga-FAPI PET/CT in patients with nasopharyngeal carcinoma: a single-center, prospective study.2024 · Eur J Nucl Med Mol Imaging · Prospective
- Diagnostic performance of [68Ga]DOTATATE PET/CT, [18F]FDG PET/CT, MRI of the spine, and whole-body diagnostic CT and MRI in the detection of spinal bone metastases associated with pheochromocytoma and paraganglioma.2024 · Eur Radiol · Prospective
- [Ga68] DOTATATE PET/MRI-guided radiosurgical treatment planning and response assessment in meningiomas.2024 · Neuro Oncol · Prospective
- Efficacy and Safety of 225 Ac-DOTATATE in the Treatment of Neuroendocrine Neoplasms With High SSTR Expression.2024 · Clin Nucl Med · Prospective
- Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study.2024 · J Nucl Med · Prospective · Phase II
- The potential of somatostatin receptor 2 as a novel therapeutic target in salivary gland malignant tumors.2021 · J Cancer Res Clin Oncol · Prospective, retrospective
- Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma.2019 · Front Oncol · Prospective, retrospective
- 64Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy.2019 · J Nucl Med · Prospective
- Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.2013 · J Nucl Med · Prospective
- Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.2013 · Recent Results Cancer Res · Prospective
- An FDG-first functional imaging approach in phaeochromocytoma and paraganglioma.2026 · Front Endocrinol (Lausanne) · Retrospective
- Semiquantitative SSTR PET metrics show molecular-morphologic discordance after 177Lu-DOTATATE in gastroenteropancreatic neuroendocrine neoplasms: an exploratory paired target-lesion analysis.2026 · Ann Nucl Med · Retrospective
- Estimation of split renal function on PET using the SSTR-targeting radioligands [18F]SiTATE, [68Ga]Ga-DOTA-TATE and [68Ga]Ga-DOTA-TOC in a theranostic setting.2026 · Eur J Nucl Med Mol Imaging · Retrospective
- Shifts in Urbanicity-Based Access to Radiotracers for Neuroendocrine Tumors.2026 · J Am Coll Radiol · Retrospective
- Diagnostic performance of somatostatin receptor positron emission tomography in preoperative evaluation of pancreatic neuroendocrine tumor lymph node metastases.2026 · Surgery · Retrospective
- Diagnostic value of ⁶⁸Ga-DOTATATE PET/CT volumetric parameters in differentiating adrenal lesions.2026 · Ann Nucl Med · Retrospective
- Meningioma theranostics: a retrospective analysis of somatostatin receptor PET/CT imaging and peptide receptor radionuclide therapy.2026 · Eur J Nucl Med Mol Imaging · Retrospective
- 68GA DOTATATE PET in Schwannomas: Distinct Avidity Pattern Supporting Noninvasive Diagnosis.2026 · AJNR Am J Neuroradiol · Retrospective
- [A rare case of adrenal hemangioblastoma and literature review].2026 · Zhonghua Nei Ke Za Zhi · Retrospective
- Anatomical-biochemical discordance and prognostic role of bone metastases in advanced MTC treated with [¹⁷⁷Lu]Lu-DOTA-TATE.2025 · BMC Cancer · Retrospective
- SUV-max of 68Ga-DOTATATE PET/CT correlates with WHO grade and RNA risk classification in meningioma.2025 · J Neurooncol · Retrospective
- Outcomes of 68Ga-NODAGA-Exendin-4 PET/CT Guided Surgical Management of Insulinomas in MEN1: A Preliminary Study.2025 · Nuklearmedizin · Retrospective
- Succinate dehydrogenase-related pheochromocytoma and paraganglioma (SDHx-PPGL): clinical and genetic insights from an Indian study.2025 · Endocr Connect · Retrospective
- CREBBP Mutation as a Culprit for Negative SSTR2 PET in Neuroendocrine Tumors.2025 · Mol Imaging Biol · Retrospective
- Clinical Profile, Outcomes, and Predictors of Malignant Pheochromocytoma and Paraganglioma: Insights From a Single-Center Cohort.2025 · Clin Endocrinol (Oxf) · Retrospective
- [68Ga-DOTATATE and 18F-FDG PET/CT dual-modality imaging enhances precision of staging and treatment decision for gastroenteropancreatic neuroendocrine neoplasms].2025 · Nan Fang Yi Ke Da Xue Xue Bao · Retrospective
- Somatostatin Receptor Expression of Gastroenteropancreatic Neuroendocrine Tumors: A Comprehensive Analysis in the Era of Somatostatin Receptor PET Imaging.2025 · Cancers (Basel) · Retrospective
- Outcomes of 68Ga-NODAGA-Exendin-4 PET/CT Guided Surgical Management of Insulinomas in MEN1: A Preliminary Study.2025 · Horm Metab Res · Retrospective
- Physiological bio-distribution of 68Ga-DOTA-TATE in pediatric patients.2025 · Ann Nucl Med · Retrospective
- Characterization of metabolic and imaging profiles in the diagnosis of succinate dehydrogenase- related hereditary pheochromocytomas and paragangliomas.2025 · Urol Oncol · Retrospective
- Full-Body Tumor Response Heterogeneity of Metastatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radiopharmaceutical Therapy.2025 · J Nucl Med · Retrospective
- Eliminating the second CT scan of dual-tracer total-body PET/CT via deep learning-based image synthesis and registration.2025 · Eur J Nucl Med Mol Imaging · Retrospective
- Outcome of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Progressive Metastatic Neuroendocrine Tumors from a Tertiary Care Center.2024 · Indian J Endocrinol Metab · Retrospective
- Enhancing precision: A predictive model for 177Lu-DOTATATE treatment response in neuroendocrine tumors using quantitative 68Ga-DOTATATE PET and clinicopathological biomarkers.2024 · Theranostics · Retrospective
- Mid-Treatment Response to 177-Lutetium Dotatate Predicts Overall Outcome in Patients With Advanced Neuroendocrine Tumors.2024 · JCO Oncol Pract · Retrospective
- Quantitative SSTR-PET/CT: a potential tool for predicting everolimus response in neuroendoctine tumour patients.2024 · Radiol Oncol · Retrospective
- Assessing Krenning's score on 68 Ga-DOTATATE PET-CT and miPSMA score on 68 Ga-PSMA-11 PET-CT in TENIS: a comparison with FDG PET/CT and examining the feasibility of targeted radionuclide therapy.2024 · Nucl Med Commun · Retrospective
- Outcome prediction of SSTR-RADS-3A and SSTR-RADS-3B lesions in patients with neuroendocrine tumors based on 68Ga-DOTATATE PET/MR.2024 · J Cancer Res Clin Oncol · Retrospective
- Parametric net influx rate imaging of 68Ga-DOTATATE in patients with neuroendocrine tumors: assessment of lesion detectability.2024 · Ann Nucl Med · Retrospective
- Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China.2024 · Eur J Nucl Med Mol Imaging · Retrospective
- The Clinical Utility of Gallium-68-DOTATATE Positron Emission Tomography Scanning in Medullary Thyroid Cancer.2024 · Endocr Pract · Retrospective
- Clinicopathological Features of Insulinoma: A Single Tertiary Center Experience.2023 · Indian J Surg Oncol · Retrospective
- Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of DOTATATE PET Scans.2023 · J Nucl Med · Retrospective
- 68Ga-DOTATATE PET in Restaging and Response to Therapy in Neuroblastoma: A Case Series and a Mini Review.2023 · J Nucl Med Technol · Retrospective
- Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT.2022 · Pharmaceutics · Retrospective
- Efficacy and Safety of 177Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study.2022 · J Nucl Med · Retrospective
- Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient's therapy course.2021 · PLoS One · Retrospective
- Comparison of 18 F-FDG PET/CT and 68 Ga-DOTATATE PET/CT in the Targeted Imaging of Culprit Tumors Causing Osteomalacia.2021 · Orthop Surg · Retrospective
- The utility of 68Ga-DOTATATE PET/CT in localizing primary/metastatic pheochromocytoma and paraganglioma in children and adolescents - a single-center experience.2021 · J Pediatr Endocrinol Metab · Retrospective
- Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant 18FDG Uptake.2021 · Neuroendocrinology · Retrospective
- Diagnostic utility of Gallium-68-somatostatin receptor PET/CT in ectopic ACTH-secreting tumors: a systematic literature review and single-center clinical experience.2019 · Pituitary · Retrospective
- 68 Ga-Pentixafor PET/CT as a Noninvasive Alternative in Evaluation of Suspected Aldosterone-producing Adenoma.2026 · Clin Nucl Med · Clinical study
- Metachronous Ectopic CRH-Secreting Tumors Detected by 68 Ga-Pentixafor PET/CT.2026 · Clin Nucl Med · Clinical study
- A Masquerading Return: When Metastatic Renal Cell Carcinoma Recurs After 20 Years to Mimic a Pancreatic Neuroendocrine Tumor on Somatostatin Receptor PET Imaging.2026 · Clin Nucl Med · Clinical study
- Superior Diagnostic Performance of ⁶⁸Ga-FAPI PET/CT Compared With ⁶⁸Ga-DOTATATE PET/CT in Medullary Thyroid Carcinoma.2026 · Clin Nucl Med · Clinical study
- Ectopic Adrenocorticotropic Hormone Syndrome Secondary to Pulmonary Neuroendocrine Tumor: Medical Stabilization Enables Serial Imaging and Localization.2026 · AACE Endocrinol Diabetes · Clinical study
- False Uptake of 18F-MFBG and 68Ga-DOTATATE in the Stellate Ganglion in a Pediatric Patient With Neuroblastoma.2026 · Clin Nucl Med · Clinical study
- In Vivo Imaging of the Innate Immune System in the Pancreas in New-Onset and Long-Standing Type 1 Diabetes.2026 · Diabetes Obes Metab · Clinical study
- Multimodal Functional Imaging in Tumor-induced Osteomalacia: 68Ga-DOTATATE, 18F-FDG, and 68Ga-FAPI PET/CT Findings.2026 · Mol Imaging Radionucl Ther · Clinical study
- Gluteal hemangioma mimicking a neuroendocrine tumor: pitfalls in neuroendocrine tumor diagnostic testing.2026 · JCEM Case Rep · Clinical study
- Evaluation of ultrasonographic and clinicopathological features of patients with abnormal [68Ga]Ga-DOTA-TATE uptake in the thyroid gland.2026 · EJNMMI Res · Clinical study
- [68Ga]-DOTATATE PET Standardized Uptake Value Reduction after Bevacizumab in High-grade Meningioma: A Potential Treatment Response Biomarker.2026 · AJNR Am J Neuroradiol · Clinical study
- Single-Stage Lesion Identification in $^{68}$Ga-DOTATATE PET Images.2026 · IEEE Trans Biomed Eng · Clinical study
- Tumor-induced osteomalacia caused by phosphaturic mesenchymal tumor in the thoracic spine: an uncommon site.2026 · J Diabetes Metab Disord · Clinical study
- Endoscopic ultrasound-guided radiofrequency ablation of pancreatic insulinoma.2026 · BMJ Case Rep · Clinical study
- Head-to-Head Comparison of [68Ga]Ga-DOTATATE PET/CT and [68Ga]Ga-NODAGA-LM3 PET/CT.2026 · J Nucl Med · Clinical study
- Molecular Deconvolution of Circulating "Other Cells": A Reliable Predictive Marker of Therapy Response and Survival in Neuroendocrine Tumor Patients Receiving 177Lu-DOTATATE PRRT.2026 · Cancer Med · Clinical study
- FAP-targeted Radio-ligand Therapy in Pancreatic Neuroendocrine Tumor: A Potential Alternative to PRRT.2026 · Clin Nucl Med · Clinical study
- Synthesis, preclinical evaluation, and clinical translation of [68Ga]Ga-Asp2-JR11, a SSTR2 antagonist for PET imaging of neuroendocrine neoplasms.2026 · Eur J Nucl Med Mol Imaging · Clinical study
- 68 Ga-DOTATATE Uptake in Pulmonary Lymphangitic Carcinomatosis: A Rare Form of Metastasis in Pediatric Neuroblastoma.2026 · Clin Nucl Med · Clinical study
- A Rare Case of Retroperitoneal Teratoma Mimicking Paraganglioma on Multimodality Imaging.2026 · Clin Nucl Med · Clinical study
- Insulin Autoimmune Syndrome: Imaging Findings and Uptake Pattern With 68 Ga-Exendin-4 and 68 Ga-DOTATATE PET-CT.2026 · Clin Nucl Med · Clinical study
- [203/212Pb]Pb-VMT-α-NET as a novel theranostic agent for targeted alpha radiotherapy-first clinical experience.2025 · Eur J Nucl Med Mol Imaging · Clinical study
- First-in-human study of an optimized, potential kit-type, SSTR antagonist 68Ga-DATA5m-LM4 in patients with metastatic neuroendocrine tumors.2025 · Theranostics · Clinical study
- Breast Metastases From ACTH Secreting Thymic Carcinoid.2025 · Clin Nucl Med · Clinical study
- Dilemma on Pancreatic Uncinate Process Uptake on Ga68-DOTA Peptide PET/CT in Pediatric Neuroblastoma: Physiologic or Metastases?2025 · Curr Radiopharm · Clinical study
- Evaluation of Inflammatory Activity of Extraocular Muscles in Thyroid Associated Orbitopathy by [68Ga]DOTATATE PET/CT.2025 · Mol Imaging Biol · Clinical study
- Tumour-induced osteomalacia.2024 · Natl Med J India · Clinical study
- Case Series: ATRX Variants in Four Patients with Metastatic Pheochromocytoma.2024 · Front Endocrinol (Lausanne) · Clinical study
- Somatostatin receptors in fibrotic myocardium.2024 · PLoS One · Clinical study
- Defining the optimal segmentation method for measuring somatostatin receptor expressing tumor volume on 68 Ga-DOTATATE positron emission tomography/computed tomography to predict prognosis in patients with gastroenteropancreatic neuroendocrine tumors.2024 · Nucl Med Commun · Clinical study
- Heterogeneous Uptake of 68 Ga-DOTATATE and 18 F-FDG in Initial Diagnosed Neuroendocrine Tumors Patients : Which Patients Are Suitable for Dual-Tracer PET Imaging?2024 · Clin Nucl Med · Clinical study
- 3-[18F]Fluoro-para-hydroxyphenethylguanidine (3-[18F]pHPG) PET-A Novel Imaging Modality for Paraganglioma.2024 · J Endocr Soc · Clinical study
- Tumour-Induced Osteomalacia-A Long Way to the Diagnosis Facilitated by [68Ga]Ga-DOTATATE PET/CT.2024 · J Clin Med · Clinical study
- Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours, UK.2023 · BMJ Open · Clinical study · Phase I
- Dynamic 68Ga-DOTA0-Tyr3-octreotate positron emission tomography-computed tomography for the evaluation of pancreatic neuroendocrine tumors: a pilot study.2023 · Quant Imaging Med Surg · Clinical study
- Imaging Pathway of a Pediatric Patient with Succinate Dehydrogenase B-Deficient Paraganglioma.2023 · J Nucl Med Technol · Clinical study
- Atorvastatin lowers 68Ga-DOTATATE uptake in coronary arteries, bone marrow and spleen in individuals with type 2 diabetes.2023 · Diabetologia · Clinical study
- The comparison of three different molecular imaging methods in localization and grading of insulinoma.2023 · Front Endocrinol (Lausanne) · Clinical study
- Comparison of 99mTc radiolabeled somatostatin antagonist with [68 Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor.2023 · Eur J Nucl Med Mol Imaging · Clinical study
- Feasibility and therapeutic potential of the 68Ga/177Lu-DOTATATE theranostic pair in patients with metastatic medullary thyroid carcinoma.2023 · Ann Endocrinol (Paris) · Clinical study
- Feasibility and Therapeutic Potential of Combined Peptide Receptor Radionuclide Therapy With Intensive Chemotherapy for Pediatric Patients With Relapsed or Refractory Metastatic Neuroblastoma.2021 · Clin Nucl Med · Clinical study
- Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using 68Ga-DOTATOC and 68Ga-DOTATATE.2020 · J Nucl Med · Clinical study
- Parametric Net Influx Rate Images of 68Ga-DOTATOC and 68Ga-DOTATATE: Quantitative Accuracy and Improved Image Contrast.2017 · J Nucl Med · Clinical study
- Role of (68)Ga somatostatin receptor PET/CT in the detection of endogenous hyperinsulinaemic focus: an explorative study.2016 · Eur J Nucl Med Mol Imaging · Clinical study
- Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging.2014 · BMC Cancer · Clinical study
- Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.2014 · J Nucl Med · Clinical study
- Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: a single centre experience.2012 · J Oncol · Clinical study
- Primary Ovarian Neuroendocrine Neoplasm With Carcinoid Syndrome and Carcinoid Heart Disease.2026 · Ochsner J · Case report
- Alternating Therapy With Osilodrostat and Etomidate in Severe Ectopic Cushing's Syndrome Complicated by Silent Bowel Perforation.2026 · Case Rep Endocrinol · Case report
- Ectopic Cushing Syndrome due to an Adrenocorticotropic Hormone-Producing Pheochromocytoma.2026 · AACE Endocrinol Diabetes · Case report
- A Novel Neurofibromatosis Type 1 (NF1) Frameshift Mutation Associated With Atypical Hypotensive Pheochromocytoma: A Case Report.2026 · Cureus · Case report
- Tumor induced-osteomalacia caused by a phosphaturic mesenchymal tumor in the sartorius muscle: a case report.2026 · Front Endocrinol (Lausanne) · Case report
- A Case of Functional Para-Aortic Paraganglioma Causing Accelerated Hypertension in an HIV-Positive Patient With Negative 68Ga-DOTATATE PET/CT Findings: Successful Laparoscopic Management.2026 · Cureus · Case report
- Diffuse and Prolonged Bone Pain Revealing Tumor-Induced Osteomalacia: A Case Report.2026 · Clin Case Rep · Case report
- A rare case of ectopic cushing's syndrome caused by renal neuroendocrine tumor.2026 · J Diabetes Metab Disord · Case report
- Nonmetastatic Pulmonary Carcinoid Presenting With Carcinoid Syndrome Despite Negative 5-HIAA: A Case Report.2026 · Case Rep Endocrinol · Case report
- Tumor-Induced Osteomalacia Mimicking Metastases on Ga-68 DOTATATE Scan: A Rare Pericytic Variant of Phosphaturic Mesenchymal Tumor.2026 · Radiol Case Rep · Case report
- All-in-One Case: Comprehensive Detection of VHL Syndrome With 68 Ga-DOTATATE PET/CT.2026 · Clin Nucl Med · Case report
- A rare case: solitary fibrous tumor with widespread metastasis on [68Ga]Ga-DOTATATE PET/CT.2026 · Eur J Nucl Med Mol Imaging · Case report
- Diffusely Increased Bone Marrow Uptake on DOTATATE PET/CT Due to PRRT-related Myelodysplasia Syndrome.2026 · Clin Nucl Med · Case report
- Gallbladder Neuroendocrine Tumor and 177 Lu DOTATATE: High Somatostatin Receptor Expression Without Clinical Response.2026 · Clin Nucl Med · Case report
- False-positive Uptake in Splenic Hamartoma on 68 Ga-DOTATATE PET/CT.2026 · Clin Nucl Med · Case report
- Cranial Reconstruction for Infiltrative Meningioma Using 68 Ga-DOTATATE Positron Emission Tomography/Computed Tomography and Individual Patient Solutions CaseDesigner®: A Case Series.2026 · Oper Neurosurg · Retrospective, case report
- Complete surgical resection of cortisol secreting neuroendocrine thymic tumour: a case report.2025 · J Cardiothorac Surg · Case report
- A Sinonasal Paranasal Mesenchymal Tumor Associated With Tumor-Induced Osteomalacia: A Case Report and Literature Review.2025 · Ear Nose Throat J · Case report
- Incidental brain uptake of Gallium-68 DOTATATE positron emission tomography/computed tomography scan in patients with neuroendocrine tumors: a case report and literature review.2025 · Chin Clin Oncol · Case report
- Increased 68 Ga-DOTATATE Uptake in Brown Adipose Tissue in a Case of Head and Neck Paraganglioma.2025 · Clin Nucl Med · Case report
- Approach to determining etiology of hypophosphatemia in a patient with coexisting phosphaturic mesenchymal tumor and fibrous dysplasia.2025 · JBMR Plus · Case report
- Metastatic Mucinous Adenocarcinoma of Unknown Origin Showing 68 Ga-DOTATATE Uptake.2025 · Clin Nucl Med · Case report
- 68 Ga-DOTATATE Uptake in Pancreatic Ductal Adenocarcinoma.2025 · Clin Nucl Med · Case report
- Functional paraganglioma, an uncommon cause of seminoma metastasis, diagnostic and therapeutic management.2025 · Rev Esp Enferm Dig · Case report
- Identification of Wandering Masses and Tumor Heterogeneity on 68Ga-DOTATATE and 18F-FDG PET/CT in Metastatic Grade II Neuroendocrine Tumor with Increased Somatostatin Receptor Expression After Combined Chemotherapy and PRRT.2024 · J Nucl Med Technol · Case report
- Occult Pancreatic Neuroendocrine Tumor Presenting as Carcinoid Syndrome.2024 · Cureus · Case report
- A Rare Cyclic Cushing Syndrome Mystery Illustrates Diagnostic Principles.2024 · JCEM Case Rep · Case report
- Cushing Syndrome Due to a Corticotropin-Releasing Hormone- and Adrenocorticotropic Hormone-Secreting Silent Pheochromocytoma.2024 · AACE Clin Case Rep · Case report
- Intraoperative radiofrequency ablation for unresectable abdominal paraganglioma: a case report.2024 · Front Endocrinol (Lausanne) · Case report
- Case report: Rare case of a preoperatively diagnosed spermatic cord paraganglioma and literature review.2024 · Front Oncol · Case report
- Central hyperthyroidism due to an ectopic TSH-secreting pituitary tumor: a case report and literature review.2024 · Front Endocrinol (Lausanne) · Case report
- Delayed Diagnosis of Ectopic Cushing Syndrome.2024 · JCEM Case Rep · Case report
- Clinical Progression of a Paraganglioma Over Many Years in a Man With Congenital Heart Disease.2023 · AACE Clin Case Rep · Case report
- 177 Lu-DOTATATE (Lutathera) Therapy in 68 Ga-DOTATATE PET/CT-Negative Liver Metastases of a Neuroendocrine Tumor.2023 · Clin Nucl Med · Case report
- Metastatic Esophageal Adenocarcinoma Showing 68 Ga-DOTATATE Uptake.2023 · Clin Nucl Med · Case report
- Tumor-induced osteomalacia combined with increased bone resorption postoperatively: A case report.2023 · Medicine (Baltimore) · Case report
- Selective use of Peptide Receptor Radionuclide Therapy following comparative imaging of Ga-68 DOTATATE PET/CT against I-131 MIBG scintigraphy in a small Asian cohort of Adult Neuroblastoma.2021 · Med J Malaysia · Case report
- Multifocal Urinary Bladder Paragangliomas With Negative 68Ga-DOTATATE Uptake and Positive 123I-MIBG Uptake.2020 · Clin Nucl Med · Case report
- Growth hormone-secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog (90)Y-DOTATATE: case report.2016 · J Neurosurg · Case report
Precursor
- Common precursor
- DOTATATE peptide PMID 35418569 / DOI 10.1038/s41598-022-09590-2
- Suppliers seen in the literature
- DOTA-(Tyr3)-octreotate (DOTATATE) acetate salt from Bachem (Bubendorf, Switzerland)
- Cited suppliers in indexed syntheses
- ABX, AUSPEP, Bachem, Bubendorf, In-house / non-commercial (various), Nanchang Tanzhen Biological Technology Co., Ltd., piCHEM
- Typical final purification
- SPE
Need this precursor?We can point you to suppliers for [68Ga]Ga-DOTATATE, or handle the enquiry for you.
Get in touchQuality control Pharmacopoeial monograph
- Ph. Eur. monograph
- 3050 Gallium (68Ga) oxodotreotide injection
- USP monograph
- not verified the USP-NF monograph index is subscription-only and no public confirmation was found
How this set was arrived at. Base set per Ph. Eur. 0125 + monograph 3050. Ge-68 breakthrough + metal impurities: generator Ga-68 only. RECOMMEND ADD: molar activity / peptide content (saturable somatostatin-receptor target).
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [68Ga]Ga-DOTATATE.
Get in touch